Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Trial details
- Registry ID
- NCT05494697
- Drugs studied
- Rintatolimod
TrialRedline tracks 2 clinical trials sponsored by AIM ImmunoTech Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCNCT05494697 | Rintatolimod | Suspended | 2031-02Estimated |
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID ConditionsNCT05592418 | Rintatolimod | Completed | 2023-11-17Actual |
Names as written in the registry records.
NCT05494697 · AIM ImmunoTech Inc.
Before: Dec 2029. After: Feb 2031.